Foregut microbiome in development of esophageal adenocarcinoma by Liying Yang et al.
 
 
PROJECT SUMMARY 
 
Foregut microbiome in development of esophageal adenocarcinoma 
 
Liying Yang, William E. Oberdorf, Erika Gerz, Tamasha Parsons, Pinak Shah, Sukhleen Bedi, 
Carlos W. Nossa, Stuart M. Brown, Yu Chen, Mengling Liu, Michael Poles, Fritz Francois, 
Morris Traube, Navjeet Singh, Todd Z. DeSantis, Gary L. Andersen, Monika Bihan, Les Foster, 
Aaron Tenney, Daniel Brami, Mathangi Thiagarajan, Indresh Singh, Manolito Torralba, Shibu 
Yooseph, Yu-Hui Rogers, Eoin L. Brodie, Karen E. Nelson, and Zhiheng Pei. 
 
New York University School of Medicine, Lawrence Berkeley National Laboratory, The J. Craig 
Venter Institute. 
 
I. PROJECT ID NUMBER, PUBLICATION  MORATORIUM INFORMATION, 
PROJECT DESCRIPTION: 
 
This manuscript is part of a pilot effort on the part of NIH staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published.  These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects.  For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)), and the Nature Precedings HMP summary page. 
 
Project ID: 46307.  
Length of your publication moratorium: 12 months.  
 
Esophageal adenocarcinoma (EA), the type of cancer linked to heartburn due to 
gastroesophageal reflux diseases (GERD), has increased six fold in the past 30 years.  This 
cannot currently be explained by the usual environmental or by host genetic factors. EA is the 
end result of a sequence of GERD-related diseases, preceded by reflux esophagitis (RE) and 
Barrett’s esophagus (BE). Preliminary studies by Pei and colleagues at NYU on elderly male 
veterans identified two types of microbiotas in the esophagus. Patients who carry the type II 
microbiota are >15 fold likely to have esophagitis and BE than those harboring the type I 
microbiota. In a small scale study, we also found that 3 of 3 cases of EA harbored the type II 
biota. The findings have opened a new approach to understanding the recent surge in the 
incidence of EA.  
 
Our long-term goal is to identify the cause of GERD sequence. The hypothesis to be tested is 
that changes in the foregut microbiome are associated with EA and its precursors, RE and BE in 
GERD sequence. We will conduct a case control study to demonstrate the microbiome disease 
association in every stage of GERD sequence, as well as analyze the trend in changes in the 
microbiome along disease progression toward EA, by two specific aims. Aim 1 is to conduct a 
comprehensive population survey of the foregut microbiome and demonstrate its association 
with GERD sequence. Furthermore, spatial relationship between the esophageal microbiota and 
upstream (mouth) and downstream (stomach) foregut microbiotas as well as temporal stability 
of the microbiome-disease association will also be examined. Aim 2 is to define the distal 
esophageal metagenome and demonstrate its association with GERD sequence. Detailed 
analyses will include pathway-disease and gene-disease associations. Archaea, fungi and 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
10
.5
02
6.
1 
: P
os
te
d 
18
 O
ct
 2
01
0
viruses, if identified, also will be correlated with the diseases. A significant association between 
the foregut microbiome and GERD sequence, if demonstrated, will be the first step for 
eventually testing whether an abnormal microbiome is required for the development of the 
sequence of phenotypic changes toward EA. If EA and its precursors represent a 
microecological disease, treating the cause of GERD might become possible, for example, by 
normalizing the microbiota through use of antibiotics, probiotics, or prebiotics. Causative therapy 
of GERD could prevent its progression and reverse the current trend of increasing incidence of 
EA. 
 
 
 
II. DATA QUALITY:   
 
Our data quality metrics will continue to follow the guidelines that are under review for the larger 
Human Microbiome Project (HMP).  We will measure the total number of reads and bases 
generated as well as the count of base calls surpassing a QV score of 20 within the clear range 
trimmed by the Roche-provided 454 base calling algorithm software.  
 
III. DATA ANALYSIS AND PUBLICATION PLANS:   
 
Data Analysis: All data will be used to analyze the relationship between the normal controls and 
subjects with RE, BE, and EA. Temporal stability of the esophageal microbiome and the special 
relationship among the three major foregut sites, mouth, esophagus, and stomach will also be 
evaluated. Both 16S rRNA gene surveys and metagenomic shotgun sequencing will be 
conducted on all samples.  
 
Initial sequence analysis includes deconvolution of the data files in sff format which are 
transformed into untrimmed fasta files (containing base calls) and qual files (containing quality 
value, QV, scores for each base call) using Roche's software, sffinfo.  The positions of the 
clear range of each read will be recorded.  For 16S data, amplification primers and barcodes 
within each sequence will be located with BLAST using parameters "W 5 -G 2 -q -1 -F F". 
Reads from the fasta file will be sorted into the individual library corresponding to the barcode 
producing the highest BLAST score. The positions of barcodes and primers within the 
untrimmed sequence will be recorded. For metagenomic data, the reads will be sorted into 
individual libraries based on the barcode information they contain.  
 
The 16S rRNA gene segment will be determined by NAST (DeSantis, 2006) comparison to a 
reference template set:  
(http://greengenes.lbl.gov/Download/Sequence_Data/Fasta_data_files/core_set_aligned.fasta.imputed). 
Prior to taxonomic classification, base calls with QV scores under 10 will be transformed to N.  
An ergatis-based compute grid workflow (http://ergatis.sourceforge.net) will be used to classify 
all reads with at least 42 remaining non-N 8-mers using RDP's Naive Bayesian Classifier 
version 2.2 (Wang, 2007) and training set No. 6 posted March 2010 (http://rdp-
classifier.sourceforge.net).  Domain, Phylum, Class, Order, Family and Genus level groupings 
will be recorded with corresponding bootstrap values.  Trimmed sequences will be clustered at 
2% sequence divergence to create Operational Taxonomic Units and frequency tables of reads 
per OTU per sample will be used for beta-diversity analysis. 
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Metagenomic shotgun sequence data will be processed using JCVI’s metagenomic annotation 
pipeline. The metagenomic annotation pipeline identifies and assigns functions to the protein 
coding genes in a given input sample. This functional annotation will be used to identify protein 
families and pathways represented in the metagenomic data, and this will subsequently be used 
to infer the metabolic capabilities of the microbial communities in the samples. We will also use 
recruit metagenomic reads to reference genomes to identify the distribution of sequenced HMP 
relevant reference genomes in these samples and address questions of genome structure and 
variation in normal versus disease samples.  
 
Differentially abundant taxonomic groups, protein families and pathways across samples will be 
identified using count statistics. In addition, samples will be compared and clustered based on 
their genetic distances, community structures, and functional profiles, and we will attempt to 
associate the sample clusters with the collected sample metadata.  
 
 
Publication Plans: We hope to submit findings from these analyses for publication by the 
Publication Moratorium date.  
 
IV. DATA RELEASE PLAN:   
 
In keeping with NIH data release policy, all data generated through this project will be made 
available to the biomedical research community. Consistent with guidelines, the sharing of 
research data will include the rapid dissemination of research data to the scientific community in 
order to maximize the public benefit of the data produced. Data sharing will involve a website 
(http://gerd.med.nyu.edu/) for sharing research results among project investigators.  A public 
portion of the website will have links to published papers through PubMed. Besides publication, 
we will make our results available to the community of scientists interested in GERD by 
presentations at national meetings, such as the annual meetings of American Society for 
Microbiology and Digestive Disease Week. Especially, we will disseminate our findings on the 
association between GERD and the foregut microbiome to avoid unintentional duplication of 
research.  Furthermore, we would welcome collaboration with others who could make use of 
the protocols developed in this project. 
 
In accordance with the updated resource sharing policy 
(http://nihroadmap.nih.gov/hmp/datareleaseguidelines.asp) our data release will be as follows: 
 
I. All 454 sequence data inclusive of 16S rDNA and metagenomic data will be released as 
quickly as possible (on a weekly basis), to the NCBI. Any metagenomic assemblies and the 
associated annotations will also be deposited at the NCBI and to GenBank within 45 days in 
agreement with the proposed policy. The raw traces will also be deposited at the Trace Archive 
or to the Short Read Archive at NCBI/NLM/NIH. The release of the UH2 dataset to dbGaP and 
to SRA occurred on July 1, 2010. 
 
II. Wherever possible, we will work closely with the HMP Data Analysis and Coordination Center 
(DACC) to coordinate standardization, and data release. 
 
III. Metadata will also be submitted to public repositories, and any human sequence or clinical 
data that could potentially be used as an identifier will be submitted to NCBI’s dbGaP (a 
controlled access database). These data are screened for human genome sequence by NCBI 
prior to deposition into the open access portion of SRA. 
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IV. Any analyses that are performed on the datasets that are generated through this project will 
be made available to the public via the DACC as soon as our manuscripts are accepted for 
publication. 
 
V. CONTACT PERSON:  
 
Dr. Zhiheng Pei, New York University School of Medicine, 212-951-5492, 
zhiheng.pei@med.nyu.edu. 
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